Home Blog Page 2928

Noah Holdings and ARK Wealth Hosts Inaugural Global Chinese Wealth Management and Inheritance Summit in Singapore

—— Shaping Resilient and Innovative Allocation Strategies for the Future

SINGAPORE, Aug. 1, 2025 /PRNewswire/ — Noah Holdings Limited’s (“Noah” or “the Company”) (NYSE: NOAH, HKEX: 6686) global wealth management platform for global Chinese investors, ARK Wealth Management (“ARK Wealth”), held its inaugural ARK Global Chinese Wealth Management and Inheritance Summit (the “Summit”) on August 1, 2025, at the Ritz-Carlton in Singapore.


The event marks the Company’s first major international event since establishing its overseas headquarters for ARK Wealth in Singapore earlier this year, and carried special significance as it coincided with Singapore’s 60th anniversary of independence. To honor the milestone, Noah Philharmonic Orchestra held a charity concert at the Esplanade – Theatres on the Bay performing arts center, offering a cultural tribute to the city-state and reflecting Noah and ARK Wealth’s long-term commitment to the region.

Attended by approximately 500 investors, executives, academics, and wealth management professionals from across the globe, the Summit featured nearly 30 speakers who addressed key themes shaping today’s financial landscape, including macroeconomic trends, investment strategies for turbulent times, multigenerational wealth transfer, and the innovation-driven structural shifts impacting capital markets.

Jingbo Wang, Co-Founder and Chairwoman of Noah Holdings, commented: “For 20 years, Noah has stood by our clients through global change. Hosting this inaugural Summit in Singapore at the time of its 60th anniversary is not only a tribute to the city-state’s unique role as a global financial hub, but also a reaffirmation of our long-term commitment to building trust and resilience for global Chinese investors.” 


Zander Yin, CEO of Noah Holdings Limited, added, “This is not just a gathering; it is a strategic signal. Singapore is not only our new overseas headquarters, but also a vital hub for fostering cross-border discussions on wealth, trust, and resilience. As global Chinese investors face rising uncertainty, we believe strategic asset allocation, technological alignment, and adopting a long-term view will define the next chapter in responsible wealth management.”

Global Perspectives: Resilience in an Age of Economic Turbulence

Renowned global speakers opened the summit by sharing their views on how investors can navigate a multipolar, fractured global economy.

Jim Rogers, investor, financial commentator, and Co-Founder of the Quantum Fund reflected on recurring patterns in history and the importance of geographic diversification and contrarian investing, stressing, “History doesn’t repeat word for word but the story is always familiar. Watch where the money is going, and don’t be afraid to wait for the right moment.”

Professor Danny Quah, Li Ka Shing Professor in Economics at the Lee Kuan Yew School of Public Policy, National University of Singapore, explored Asia’s growing role in the global order, stating, “The global center of gravity is moving eastward, not just economically, but also in policymaking and innovation. Multilateralism is not dead; it is being redefined. This presents both opportunity and responsibility for the region’s wealth holders.”

In a pre-recorded fireside chat with Zander Yin, Author of The Black Swan, and Antifragile, Nassim Nicholas Taleb, explored how investors can thrive amid disorder. Drawing on his experience of living through the Lebanese civil war in the 70’s, Taleb noted that crises often escape prediction, not because there are no warning signs, but because vulnerabilities are ignored. He encouraged Chinese investors to adopt barbell strategies—combining ultra-safe assets with asymmetric, high-risk bets that benefit from volatility. To build resilience in wealth structures, he emphasized the importance of decentralization, low leverage, and high optionality—principles critical to navigating an increasingly complex and fragile world.

CIO Report: Hedging Against Inflation to Tech-Driven Deflation

During the summit, ARK Wealth released its 2025 H2 CIO Report, outlining a fundamental shift from inflation-hedged asset allocation to a technology-deflation paradigm. The report argues that while the past two decades focused on hedging against inflation and allocating to inflation-hedged assets, the next twenty years could be defined by understanding, embracing, and capitalizing on deflation driven by technological progress.

Thematic Panels: Navigating Innovation, Digital Transformation, and Global Expansion

A series of in-depth panel discussions brought together leading experts to explore how emerging technologies, shifting geopolitics, renewable energy, and alternative assets are reshaping portfolios and capital allocation. Discussions spanned the resilience of private credit, the inflation-hedging qualities of infrastructure, clean energy opportunities, the evolution of digital assets and tokenization, frameworks for alternative asset allocation, and Singapore’s enabling role as a launchpad for Noah’s global strategy. The interactive sessions sparked valuable exchanges, with audience members gaining actionable insights for navigating the challenges and opportunities ahead.

Looking Ahead

The success of the inaugural Summit reflects the Company’s global perspective, forward-looking approach to strategic wealth management, and its commitment to serve global Chinese investors across geographies with trust, sophistication, and long-term partnership.

– End –

About Noah Holdings Limited and ARK Wealth Management

Noah Holdings Limited (NYSE: NOAH and HKEX: 6686) is a leading and pioneer wealth management service provider offering comprehensive one-stop advisory services on global investment and asset allocation primarily for global Chinese high-net-worth investors. Noah’s American depositary shares, or ADSs, are listed on the New York Stock Exchange under the symbol “NOAH,” and its shares are listed on the main board of the Hong Kong Stock Exchange under the stock code “6686.” One ADS represents five ordinary shares, par value $0.00005 per share.

ARK Wealth Management, a core subsidiary under Noah Holdings Limited, is a leading provider of global wealth management services, offering one-stop financial solutions for high-net-worth global Chinese families and institutions. With a client-centric philosophy that emphasizes independence and professionalism, ARK consistently innovates its product offerings and services to address the evolving needs of its clients, delivering sophisticated wealth management strategies with a goal of becoming the preferred wealth management platform for global Chinese investors.

ARK Wealth Management currently has over USD 8.7 billion in assets under advisement (AUA). With service centers in multiple countries and regions, ARK’s team of 140+ global investment advisors focus on providing tailored, localized financial services to clients.

 

“Hong Kong Cat Expo 2025” Officially Opens

The Hong Kong’s Largest Cat-Themed Event

 

HONG KONG, Aug. 1, 2025 /PRNewswire/ — Organized by Exhibition Group, the “Hong Kong Cat Expo 2025” is being held from August 1 to 3 (Friday to Sunday) at Hall 3BCD of the Hong Kong Convention and Exhibition Centre.  As Hong Kong’s largest cat-themed event, “Hong Kong Cat Expo 2025” brings together local and international creative cat-themed art, products, trendy toys, and lifestyle goods, creating the perfect shopping and leisure destination for cat lovers. This year, the Expo adopts the theme of “Ancient Egypt” and features over 180 exhibitors and 380 booths, all dedicated to promoting cat culture. The venue will feature a 4-meter-tall pyramid and an art installation of “Tutan ‘MEOW’ mun” featuring LeonLollipop’s iconic Gloomie cats. The Expo also offers a series of exciting activities and themed zones, including the CFA WCC Cat Show Competition, the “Meowsterpieces”, and the MoCity x Cat is Cat “Purrfect Cat Talk”, offering cat lovers the summer’s most eye-catching experience.

“Hong Kong Cat Expo 2025” Officially Opens.
“Hong Kong Cat Expo 2025” Officially Opens.

The opening ceremony was officiated by Dr Bernard Chan, Under Secretary for Commerce and Economic Development of the Government of the Hong Kong Special Administrative Region, Mr. SHIU Ka-fai, Member of the CPPCC National Committee and Legislative Council, Mr. Benson Luk, Member of Legislative Council, Dr. Michelle Yeung, Principal Veterinary Officer of the Agriculture, Fisheries and Conservation Department, Mr. Jason Wong, Chairman of the Culture, Sports and Tourism Affairs Committee of the BPA, Mr. Rex Li, Chairman of Hong Kong Pet Trade Association Limited, Ms. Helena Chen, Senior Vice President, General Manager of Mastercard Hong Kong and Macau, Mr. Jan van Rooyen, President of World Cat Congress, Ms. Yoko Tsang, Cat Lover Ambassador and Mr. Carl Wong, Chairman of Exhibition Group.

Mr. Carl Wong, Chairman of the Exhibition Group, stated: “The ‘pet community economy’ can extend the traditional pet industry to the friends of pet owners and beyond, injecting new vitality into Hong Kong’s economy. This year, the expo is collaborating with the Hong Kong Palace Museum for synergistic promotion. As always, the expo provides a one-stop platform offering the most comprehensive range of cat-related products and information. Moreover, we have innovatively invited cat-themed cultural and creative arts from around the world, to enrich the cultural depth of the ‘pet community economy’. We hope the Cat Expo will not only be a showcase for products and industries but also evolve into a cultural celebration of the ‘ pet community economy’.”

Hong Kong’s pet industry (cat sector) has seen steady growth in recent years, with the market size now exceeding HKD 2.4 billion annually. Recent surveys indicate that the average monthly spending of cat owners in Hong Kong has surpassed HKD 2,000, marking a 6.2% increase from last year. The high-spending consumer base continues to expand, demonstrating the robust momentum and vast market potential of the “cat economy.” The “cat economy” has become a new engine for local consumption, spanning multiple sectors including food, supplies, healthcare, services, cultural & creative products, and even pet-friendly tourism. Not only does it inject sustained vitality into the local economy, but it also fosters community harmony and enhances residents’ happiness.

Apart from pet products, the “Hong Kong Cat Expo 2025” is bringing in art toys and creative art from regions such as China, Thailand, Japan, and Korea, further driving both local and international creative developments. This year, the Expo specially invites Local Hong Kong illustrator Mandycat to create a unique art installation inspired by Hong Kong’s nostalgic “Jau Gwal Dong”, blending local culture and cat elements for visitors to enjoy. The venue also features a “Meowsterpieces”, in collaboration with local galleries including Artaflo Collective and BLINK Gallery, exhibiting works from about 20 artists from China, France, Japan, India, Russia, Malaysia, and more, all themed around cats. Artaflo Collective spotlights three artists: Chinese artist Li Yueling’s “Happy Hour” created specially for the Expo; Hong Kong artist Billy Hung’s large-scale Lucky Cat neon-inspired work; and Malaysian artist Chun Yu’s sand-based Kakaland series.

During the Expo, “MoCity x Cat is Cat” will co-host the “Purrfect Cat Talk”, covering topics such as breeds, care, nutrition, food selection, and veterinary knowledge. Experts will share tips on raising cats, health management, and food selection, providing the latest scientific and natural nutrition insights. The Hong Kong Black Cat Club will also host the CFA WCC Cat Show Competition, successfully bringing the World Cat Congress (WCC), known as the “United Nations of the Cat World,” to Hong Kong for the first time. Professionals from Australia, China, Finland, France, Germany, Russia, Singapore, South Africa, Thailand, the US, and Hong Kong will share the latest cat medical, welfare, and health information, and offer free public seminars to promote professional cat knowledge and foster international exchange.

This year’s Expo will showcase many popular and creative pet brands, offering a wide variety of choices for pet owners. Featured brands include: One Two Ceramic (Booth 3B-R21) from Taiwan, a creative ceramics brand using hand-painted glazing for unique pieces; Thailand’s Sofubi curatorial team Codecorner (Booth 3C-Z03) has collaborated with ten artists to create the ‘We Are All Cats’ themed zone, featuring exclusive first releases of limited-edition cat-themed designer merchandise at the event; Twenty.Two.April (Booth 3B-P50), a Thai handmade accessory brand, offers unique jewelry including earrings, bracelets, necklaces, keychains, and hair accessories, all with adorable cat motifs; MEimo (Booth 3B-P38) presents the healing character Lukchin Cat through illustrations and merchandise; Hong Kong building block brand JEKCA (Booth 3B-R19), designed for adults, features over 1,000 themed block sculptures to deliver the ultimate building experience; Space Shi Sliver Jewelry Studio(Booth 3B-N19), using patented technology to turn pet hair into unique “life diamonds” as lasting mementos for pet owners; VIPETS LTD (Booth 3C-F01), offering premium pet food and care products from around the world, with a special on Trilogy cat cans at only $1 for the first 24 customers daily.

During the Expo, the “Cats On The Big Screen” displays beautiful photos of cats provided by their owners on the stage’s big screen, allowing cat lovers to selfie with their cats in front of it. Customers who spend HK$250 with a single receipt using a Mastercard® at designated booths in the exhibition venue will have one chance to enter a lucky draw; HK$500 gets two chances, and so on, up to 10 chances per receipt. Only printed receipts are accepted, and Customers can redeem scratch cards at the activity area to instantly reveal their prize. Prizes include round-trip tickets for two to Tokyo, Seoul, and Taipei, with over 3,000 prizes worth over HK$140,000 in total. (Trade Promotion Competition Licence No: 060137, 060138; Offers are subject to relevant terms and conditions.) Attendees who “Like” the “Hong Kong Cat Expo” Facebook page and follow on Instagram can get a free pair of cat ear headbands (daily limited to 2,000 pieces, while stocks last).

Hong Kong Cat Expo 2025

Date

1 to 3 August 2025 (Friday to Sunday)

Time

1 to 2 August (Friday to Saturday): 12:00 noon to 9:00 PM

3 August (Sunday): 12:00 noon to 8:00 PM

Venue

Hall 3BCD, HKCEC

Website

 https://www.exhibitiongroup.com.hk/exhibitions/catexpo2025

 

About Exhibition Group

Exhibition Group Limited is one of Hong Kong’s renowned exhibition companies. Our core team has been assembled since 2003, bringing together a group of innovative, experienced, and professional exhibition talents. As a leading event management company, specializing in the planning and operation of world-class public exhibitions, conferences, and trade fairs, covering a wide range of industries. With years of industry experience, we are committed to the development of exhibition and marketing businesses, gaining a prestigious reputation within the exhibition industry.

Our company organizes a variety of themed exhibitions and marketing projects, which not only receive substantial support from the business community and exhibitors but also effectively attract a large number of public participants. Each event has garnered rave reviews, resulting in a win-win situation for exhibitors in both product promotion and sales. Notable exhibitions include the Pet Show, In-Home Expo, Premium Pet Supplies Expo, Hong Kong Cat Expo, Hong Kong Holiday & Travel Expo, Extracurricular Activities Festival cum Teaching Materials and Supplies Expo, and Hong Kong Outdoor & Sports Expo, among others. In recent years, our company has been honored with several awards, including the “Outstanding Award for Pandemic Resilience,” “ESG Commendation Awards,” and “Innovative Exhibition Planning,” recognizing our business development achievements across various sectors.

This press release is distributed by Market Hubs Holdings Limited.

 

For Media Enquiry,

Market Hubs Holdings Limited

Lierence Li

Debbie So

+852 3998-4900

+852 3998-4900

lierence@markethubsgroup.com

debbie@markethubsgroup.com

Kary Chan

+852 3998-4900

kary@markethubsgroup.com

 

 

 

Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA

SHANGHAI, Aug. 1, 2025 /PRNewswire/ — Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911, has received Investigational New Drug (IND) application acceptance from China’s National Medical Products Administration (NMPA) and an IND Acknowledgement Letter from the U.S. Food and Drug Administration (FDA).

7MW4911 is an investigational CDH17-targeting ADC developed using Mabwell’s proprietary IDDC™ platform. Its highly optimized structure integrates three key elements:

  • Mab0727: A highly specific CDH17 monoclonal antibody with rapid internalization properties, cross-species (human/monkey) moderate affinity, and minimal off-target binding.
  • Novel cleavable linker: Ensures precise payload release in tumor tissues.
  • MF-6 payload: A proprietary DNA topoisomerase I inhibitor designed to overcome multidrug resistance (MDR), exhibiting superior plasma stability, controlled drug release, and potent bystander effects.

In July 2025, Mabwell published preclinical data in Cell Reports Medicine (“Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor”), demonstrating 7MW4911’s tumor-selective cytotoxicity via CDH17-mediated internalization. Key advantages include:

  • Optimized molecular design: Homogeneous drug-to-antibody ratio (DAR=4, >95%) and stable linker confer exceptional plasma stability, while membrane-permeable MF-6 drives potent bystander killing.
  • Broad Antitumor Efficacy: Demonstrates robust tumor regression in colorectal, gastric, and pancreatic cancer PDX/CDX models, including tumors with RAS/BRAF mutations and diverse Consensus Molecular Subtypes (CMS).
  • MDR resistance: Outperforms MMAE/DXd-based ADCs in ABC transporter-mediated MDR models and reverses tumor progression post-ADC treatment.
  • Target versatility: Active even in tumors with low-to-moderate CDH17 expression, expanding potential patient eligibility.
  • Favorable safety profile: Limited tissue distribution in mice, controllable pharmacokinetics (moderate half-life, no accumulation), and a wide therapeutic window in cynomolgus monkeys, with no significant toxicity signals.

With this profile, 7MW4911 emerges as a promising therapeutic candidate for advanced gastrointestinal cancers.

About CDH17

CDH17 is a pan-cancer validated target with restricted expression in normal intestinal epithelium but marked overexpression in gastrointestinal cancers (e.g., colorectal, gastric, pancreatic). Its aberrant expression correlates with tumor metastasis and poor prognosis, positioning it as an ideal therapeutic target.

About Mabwell

Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. The company provides more effective and accessible therapy and innovative medicines to fulfill global medical needs, focusing on oncology and aging-related disease indications. Mabwell’s mission is “Explore Life, Benefit Health” and its vision is “Innovation, from ideas to reality”. For more information, please visit www.mabwell.com/en.

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company’s product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. “Forward-looking statements” are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions and the negatives of those terms.

Forward-looking statements are based on the Company’s current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company’s control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the potential impact of COVID-19; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.

The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.

 

Dusit International signs strategic partnership for hotel development in France


PARIS, FRANCE – Media OutReach Newswire – 1 August 2025 – Dusit International, one of Thailand’s leading hotel and property development companies, has signed a strategic partnership agreement with SYDEL, a French real estate investment company, to establish Dusit France – a joint venture created to bring Dusit’s unique brand of Thai-inspired gracious hospitality to France for the first time.

Dusit International and SYDEL formally established Dusit France at a signing ceremony held in Paris. Pictured (from left): Mr Donatien Carratier, Head of Dusit France; Mr Jordan Elbaz, Partner, SYDEL; Mr Gilles Cretallaz, Chief Operating Officer, Dusit International; and Mr David Elgrably, Partner, SYDEL.
Dusit International and SYDEL formally established Dusit France at a signing ceremony held in Paris. Pictured (from left): Mr Donatien Carratier, Head of Dusit France; Mr Jordan Elbaz, Partner, SYDEL; Mr Gilles Cretallaz, Chief Operating Officer, Dusit International; and Mr David Elgrably, Partner, SYDEL.

Leveraging SYDEL’s local knowledge and operational expertise, the joint venture will focus on identifying opportunities for Dusit Hotels and Resorts, whose portfolio of nine brands spans the lodging spectrum – from affordable lifestyle hotels to full-service luxury retreats.

Brands being considered for the French market include Dusit Thani (Bespoke Luxury), Devarana – Dusit Retreats (Wellness Luxury), Dusit Collection (Character Luxury), Dusit Hotels (Upper Upscale), dusitD2 (Lifestyle Upscale), Dusit Princess (Upper Midscale), ASAI Hotels (Lifestyle Midscale), and Dusit Suites (Lifestyle Long Stay).

Together, Dusit and SYDEL will identify strategic locations, support asset owners with repositioning projects, and introduce innovative hotel concepts focused on delivering memorable guest experiences, championing well-being, and creating long-term sustainable value.

The partnership was formalised at an exclusive signing ceremony held on 10 July 2025 in Paris. At the event, Mr Gilles Cretallaz, Chief Operating Officer of Dusit International, shared the vision for Dusit France and outlined the group’s growth ambitions in the region.

“We are thrilled to partner with SYDEL to seek opportunities to expand Dusit’s footprint and bring our distinctive brand of Thai-inspired gracious hospitality to France – one of the world’s most iconic travel destinations,” said Mr Cretallaz. “This partnership marks an important milestone in our global expansion strategy, and we are confident that our unique blend of cultural authenticity, innovation, and gracious service will resonate strongly with travellers and developers alike.”

Dusit’s portfolio currently spans 294 properties across 18 countries, including 55 operating under Dusit Hotels and Resorts and 239 luxury villas under Elite Havens. In Europe, the company operates the upper-upscale Dusit Suites Athens in Greece, located in the vibrant coastal district of Glyfada on the Athenian Riviera.

Hashtag: #dusitinternational

The issuer is solely responsible for the content of this announcement.

BingX Labs Marks One Year of Web3 & AI Innovation with $16Million in Strategic Investments

PANAMA CITY, Aug. 1, 2025 /PRNewswire/ — BingX, a leading cryptocurrency exchange and Web3 AI company, announced the first anniversary of BingX Labs, its dedicated investment and incubation arm. Over the past year, BingX Labs has established itself as a key strategic investor, partner, and developer ally, driving innovation at the intersection of Web3, AI, and decentralized finance.

BingX Labs Marks One Year of Web3 & AI Innovation with $16Million in Strategic Investments
BingX Labs Marks One Year of Web3 & AI Innovation with $16Million in Strategic Investments

Since its launch in 2024, BingX Labs has committed $16 million in investments across high-impact projects and protocols such as Babylon and StakeStone, alongside strategic collaborations with leading partners including IOSG, Kaia foundation, and Hackquest to support broader Web3 and AI ecosystem growth. These partnerships exemplify BingX Labs’ approach — fostering strategic collaborations with the builders of core infrastructure for the next phase of Web3 and AI adoption.

Beyond financial backing, BingX Labs has become a hub of research and innovation. The Labs team is actively exploring key emerging sectors such as RWA (Real-World Assets), DeFi, and AI agents. With regular webinars and developer meetups, BingX Labs connects with global builder communities to share insights and collaborate on the next wave of technological breakthroughs. BingX Labs has also reinforced its position as a key player in the Web3 and AI space by sponsoring and attending major international events like Consensus and the Token 2049.

Vivien Lin, Head of BingX Labs and Chief Product Officer at BingX, commented:”In its first year, BingX Labs has evolved into more than an investment platform — it is a catalyst for the next generation of Web3 and AI innovation. By combining deep research, strategic partnerships, and strong developer engagement, we are building the infrastructure to support breakthrough projects that will shape the future of AI and decentralized technology. Looking ahead, our commitment to empowering developers and partners in these transformative sectors will continue to be our guiding principle.”

Looking ahead, BingX Labs plans to deepen its research, expand partnerships, and explore new opportunities, especially in AI-powered decentralized applications, with a continued focus on uncovering the next wave of transformative projects.

About BingX 

Founded in 2018, BingX is a leading crypto exchange and Web3 AI company, serving a global community of over 20 million users. With a comprehensive suite of AI-powered products and services, including derivatives, spot trading, and copy trading, BingX caters to the evolving needs of users across all experience levels, from beginners to professionals. Committed to building a trustworthy and intelligent trading platform, BingX empowers users with innovative tools designed to enhance performance and confidence. In 2024, BingX proudly became the official crypto exchange partner of Chelsea Football Club, marking an exciting debut in the world of sports sponsorship.

For more information please visit: https://bingx.com/

Elegoo Wraps the First Phase of “ELEGOO With Her”, Spotlighting Women Creators in Home Decor, Fashion, Cosplay, and Education

SHENZHEN, China, Aug. 1, 2025 /PRNewswire/ — Elegoo, a rapidly developing brand in global smart manufacturing, proudly announces the wrap-up of the first phase of its “ELEGOO With Her” initiative, a program supporting women creators worldwide through 3D printing. From over 110 sign-ups, 30 final participants from 17 countries stood out to join this phase. After three months of workshops and mentorship, the program now enters its showcase stage, with over 70% of participants new to 3D printing, underscoring its role in making the technology more accessible.

Elegoo wraps the first phase of “Elegoo With Her,” spotlighting women creators in home decor, fashion, cosplay, and education.
Elegoo wraps the first phase of “Elegoo With Her,” spotlighting women creators in home decor, fashion, cosplay, and education.

Launched at Formnext 2024, “ELEGOO With Her” was led by eight accomplished female designers and makers: Anouk Wipprecht, Batoul al-Rashdan, Brigitte Kock, Denise Bertacchi, Emily Boe (pseud.), Linette Manuel, Shehzeen Rehman, and Willow Creative (alias). Among the participants’ creations were STEM kits empowering girls in Africa and intricately 3D-printed lamps inspired by early 20th-century design, showcasing 3D printing’s creative potential in home decor, fashion, cosplay, and education.

“I remember how excited I was when I printed my first benchy. I also remember the failures. The hands-on workshops, mentorship, and community gave me more than just skills. They gave me the confidence to build and to lead,” said Janet Zagah, a renewable energy entrepreneur and program participant.

“Having an inclusive program run by a company as big as Elegoo is powerful,” said Kinnera Putti, a mobile developer who also participated in the program. “I hope others see what we’ve made and feel inspired to try something too.”

“We’ve always believed 3D printing should be accessible to everyone, and these projects show just how powerful it can be when women challenge themselves and use the technology to create and improve lives beyond their own,” said Coco Lee, Brand Director of Elegoo. “With proven reliability and ease of use, we’re proud that our products enable people from all backgrounds to unleash their creativity and bring their ideas to life.”

While this chapter wraps, the journey continues. Elegoo has made its workshops public on YouTube, and the next showcase will be at IFA Berlin this September, where their work will inspire more women to create.

For more information, please visit the ELEGOO With Her blog or follow Elegoo’s social media platforms.

About Elegoo

Founded in 2015, Elegoo is a rapidly developing brand in the global smart manufacturing industry, specializing in R&D, manufacturing, and sales of consumer-grade 3D printers, laser engravers, STEM kits, and other smart technology products. Located in Shenzhen, the Silicon Valley of China, the company has sold millions of products across more than 100 countries and regions. In 2024, the company’s total sales revenue surpassed 220 million USD, with more than 1000 employees and nearly 30,000 square meters of office and manufacturing area. With a focus on programming and 3D printing technology, Elegoo provides unique and smart creation spaces for diverse consumers to enhance personalized experiences.

Navigating Globalization: Dialogue on How GAC is Evolving with Technology and Talent

GUANGZHOU, China, Aug. 1, 2025 /PRNewswire/ — GAC’s global expansion is accelerating in recent years. As Chinese automakers emerge as global trendsetters in market scale, technological innovation and talent attraction, GAC stands at the forefront of this transformation. In this exclusive interview, Masato Katsumata – GAC INTERNATIONAL’s Chief Technology Officer explains why he chose to join GAC, while his endorsement reinforces GAC’s position as the focal point of China’s automotive globalization. In addition, he also discusses the evolution of vehicle technology, from traditional engines to new energy and AI-driven advancements, emphasizing a user-centric approach and the ultimate pursuit of detail.

 

Dialogue with CTO of GAC INTERNATIONAL Masato Katsumata: Focusing on Automotive Technology Evolution and Globalization Strategy

With the “One GAC 2.0” strategy that blends world-class technology with deep local market insights, GAC is redefining what it means to be a truly global automaker. Industry engineers like Katsumata are betting on GAC’s vision – where he hopes that as a world-class enterprise, GAC is committed to going global in multiple aspects, driven by cutting-edge technology and a mission to deliver excellence worldwide.

Everest Medicines Expands Strategic Investment in I-MAB

– Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%.

– I-Mab’s Claudin 18.2 x 4-1BB bispecific antibody, givastomig, demonstrated an impressive overall response rate (ORR) of 83% in combination with immunotherapy in a Phase 1b trial of first line gastric cancers.

– I-Mab’s differentiated 4-1BB receptor targeting platform and bispecific antibody pipeline are highly complementary with the Company’s existing mRNA cancer vaccines and in vivo CAR-T platform.

– Complementary and synergistic clinical development and business development platforms, especially I-Mab’s unique clinical translational capabilities, particularly in the U.S., and Everest’s clinical capabilities in Asia, could help accelerate the development and global expansion of pipeline products for both companies.

–  New investors in this offering also include Janus Henderson Investors, Adage Capital Partners LP, Woodline Partners, and Exome Asset Management

SHANGHAI, Aug. 1, 2025 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has made a strategic equity investment in I-Mab, (”I-Mab”), a company listed on the Nasdaq Global Market (”Nasdaq”) trading under the symbol ”IMAB”.

“This strategic equity investment furthers our plan to be an active player in next-generation oncology programs across global markets. Everest and its Board of Directors believe this investment recognizes I-Mab’s unique clinical translational capabilities in the U.S., which are complementary and synergistic with the Company’s strong Asia presence,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “As a biotech pioneer in China, Everest has built internally developed pipeline assets including mRNA therapeutic cancer vaccines and in vivo CAR-T therapies targeting cancer and autoimmune diseases. Our areas of focus meaningfully intersect with I-Mab’s differentiated 4-1BB platform and bispecific antibody pipeline, including oncology candidates Givastomig (Claudin 18.2 x 4-1BB bispecific antibody) and Ragistomig (PD-L1 x 4-1BB bispecific antibody), both promising programs that we are closely watching. Furthermore, both companies may be able to leverage their combined expertise to run clinical programs in both China and the U.S. Everest is proud to develop innovative and valuable therapies that can benefit cancer patients globally.”

Financial Terms and Corporate Updates:

I-Mab today announced an underwritten offering of 33,333,334 American Depositary Shares (the “ADSs”) representing 76,666,668 ordinary shares at an offering price of $1.95 per ADS, for total gross proceeds of approximately US$65 million. Under the arrangement of this offering, Everest will subscribe for 15,846,154 ADSs (the “Subscription”), with an aggregate consideration of US$30.9 million. Upon completion of the Subscription, the Company shall hold an aggregate of 15,846,154 ADSs and 6,078,571 ordinary shares, representing approximately 16.1% of the total issued share capital of I-Mab, inclusive of 6,078,571 ordinary shares already held by Everest.

As all of the applicable percentage ratios of the Subscription are less than 5%, the Subscription is not subject to the announcement or shareholders’ approval requirements under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The investment in I-Mab shares is expected to be booked as “investments” under non-current assets on Everest’s balance sheet. Changes from “mark-to-market” are expected to be reflected in fair value through other comprehensive income in the statement of changes in equity and the investment has no impact on the Company’s P/L statement and will not appear as an operating expense.

I-Mab is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. There are three pipeline products of I-Mab in clinical stage, Givastomig (Claudin 18.2 x 4-1BB bispecific antibody), Ragistomig (PD-L1 x 4-1BB bispecific antibody) and Uliledlimab (CD73 antibody).

I-Mab recently presented positive Phase 1b dose escalation results for givastomig in combination with immunotherapy in first line gastric cancer (ORR of 83%) at the ESMO GI 2025 conference which are summarized here.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders.

For more information, please visit its website at www.everestmedicines.com.

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first line metastatic gastric cancers, with additional potential in other solid tumors. In ongoing Phase 1 trials, givastomig has been observed to maintain strong tumor-binding and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents.

For more information, please visit www.i-mabbiopharma.com and follow us on LinkedIn and X.

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.